Paysign Gestione
Criteri Gestione verificati 3/4
Paysign Il CEO è Mark Newcomer, nominato in Mar2006, e ha un mandato di 20.42 anni. la retribuzione annua totale è $ 2.75M, composta da 38.1% di stipendio e 61.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 16.23% delle azioni della società, per un valore di $ 126.45M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 8.3 anni.
Informazioni chiave
Mark Newcomer
Amministratore delegato
US$2.8m
Compenso totale
| Percentuale dello stipendio del CEO | 38.12% |
| Mandato del CEO | 20.4yrs |
| Proprietà del CEO | 16.2% |
| Durata media del management | 5.8yrs |
| Durata media del Consiglio di amministrazione | 8.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Aug 19
PAYS: Higher Guidance And Pharma Program Expansion Will Shape Balanced Future Outlook
Analysts have raised their implied fair value for Paysign to $13.10 from $10.45, reflecting recent price target increases to $12, $13 and $15 after the company reported a Q2 that came in ahead of expectations and led to higher annual guidance. Analyst Commentary Bullish analysts on Paysign have reacted positively to the recent Q2 report and guidance, with several research desks lifting their price targets in quick succession.
Nuova narrativa • Aug 05
5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it
Paysign trades below the value implied by discounting its own free cash flow. On a two-stage model running 10 years of +25.0% growth fading to a 2.5% terminal rate, discounted at 9.8%, the shares are worth USD 43.01 against a market price of USD 9.17 — a 79% discount, or +369% to fair value.Aggiornamento narrativa • Aug 05
PAYS: Share Repurchase And New Pharma Programs Will Support Future Upside
Analysts raised their price target on Paysign to $11, up from a previous range of $8 to $9, citing the updated fair value estimate of $10.45 and the addition of new pharma programs as key factors supporting the change. What’s in the News for Paysign Paysign announced a share repurchase program that authorizes the company to buy back up to US$5 million of its outstanding common stock.
Aggiornamento narrativa • Jun 24
PAYS: 2026 Earnings Guidance And Margin Outlook Will Support Repricing
Analysts have maintained their $12.75 price target on Paysign, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which together support keeping the current valuation view unchanged. What’s in the News for Paysign Paysign issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$26.2 million to US$26.7 million.Aggiornamento narrativa • Jun 04
PAYS: Higher 2026 Margin Guidance And P/E Framework Will Support Repricing
Analysts have increased their price target on Paysign by $1 to $12.75, reflecting updated views on its growth, margins, and P/E assumptions. What's in the News Paysign issued earnings guidance for the first quarter of 2026, expecting revenue of US$27.0 million to US$27.5 million, with 137 active patient affordability programs and 589 plasma centers projected at quarter end.Aggiornamento narrativa • May 20
PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing
Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.Aggiornamento narrativa • Apr 30
PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions
Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.Aggiornamento narrativa • Apr 12
PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing
Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.Aggiornamento narrativa • Mar 28
PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing
The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.Articolo di analisi • Feb 05
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Articolo di analisi • Nov 16
Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...Seeking Alpha • Oct 01
Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)
Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking AlphaArticolo di analisi • Aug 09
Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...Aggiornamento narrativa • Aug 07
Digital Payment Solutions Will Expand Healthcare Access Further
Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.Articolo di analisi • May 06
Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings
Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...Articolo di analisi • Mar 04
Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...Articolo di analisi • Dec 27
Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Nov 20
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha
Nuova narrativa • Sep 26
Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures
The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.Articolo di analisi • Sep 07
Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Aug 02
Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...Seeking Alpha • Jun 30
Paysign: Expect Rapid Growth In Its Pharma Business
Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking AlphaArticolo di analisi • Apr 26
Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...Articolo di analisi • Mar 29
Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$16m |
| Mar 31 2026 | n/a | n/a | US$10m |
| Dec 31 2025 | US$3m | US$1m | US$8m |
| Sep 30 2025 | n/a | n/a | US$8m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$6m |
| Dec 31 2024 | US$1m | US$1m | US$4m |
| Sep 30 2024 | n/a | n/a | US$8m |
| Jun 30 2024 | n/a | n/a | US$8m |
| Mar 31 2024 | n/a | n/a | US$7m |
| Dec 31 2023 | US$1m | US$950k | US$6m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | US$1m |
| Mar 31 2023 | n/a | n/a | US$1m |
| Dec 31 2022 | US$3m | US$950k | US$1m |
| Sep 30 2022 | n/a | n/a | US$420k |
| Jun 30 2022 | n/a | n/a | -US$703k |
| Mar 31 2022 | n/a | n/a | -US$1m |
| Dec 31 2021 | US$963k | US$950k | -US$3m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$13m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$1m | US$950k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | US$6m |
| Mar 31 2020 | n/a | n/a | US$8m |
| Dec 31 2019 | US$1m | US$883k | US$7m |
Compensazione vs Mercato: La retribuzione totale di Mark ($USD 2.75M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 3.54M ).
Compensazione vs guadagni: La retribuzione di Mark è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Mark Newcomer (61 yo)
20.4yrs
Mandato
US$2,754,265
Compensazione
Mr. Mark R. Newcomer co-founded PaySign, Inc., (formerly known as 3Pea International, Inc.) and serves as its President from January 24, 2024, serves as Director since May 8, 2026 and has been its Chief Ex...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 20.4yrs | US$2.75m | 16.23% $ 126.4m | |
| President of Patient Affordability | 6.2yrs | US$1.54m | 0.044% $ 344.2k | |
| Chief Innovation Officer | 1.4yrs | US$1.49m | 0% $ 0 | |
| CFO & Treasurer | 5.5yrs | US$697.56k | 1.02% $ 8.0m | |
| Chief Operating Officer | 2.6yrs | Nessun dato | Nessun dato | |
| Chief Technology Officer | 5.1yrs | Nessun dato | Nessun dato | |
| Chief Compliance Officer | 8.5yrs | Nessun dato | Nessun dato | |
| General Counsel | 7.8yrs | US$699.04k | 0.93% $ 7.3m | |
| Executive Vice President of Strategy & Corporate Development | 8.4yrs | Nessun dato | Nessun dato | |
| Executive VP of EFT Operations & Executive Director | 5.5yrs | Nessun dato | 1.19% $ 9.2m | |
| Chief Payments Officer & Director | 2.6yrs | Nessun dato | 0.48% $ 3.8m | |
| Senior Vice President of Business Development | 6.2yrs | Nessun dato | Nessun dato |
5.8yrs
Durata media
59yo
Età media
Gestione esperta: Il team dirigenziale di PAYS è esperto e expertise (durata media dell'incarico 5.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | less than a year | US$2.75m | 16.23% $ 126.4m | |
| Executive VP of EFT Operations & Executive Director | 7.8yrs | Nessun dato | 1.19% $ 9.2m | |
| Chief Payments Officer & Director | 4yrs | Nessun dato | 0.48% $ 3.8m | |
| Independent Chairman of the Board | 8.3yrs | US$164.20k | 0.30% $ 2.3m | |
| Independent Director | 3.7yrs | US$164.20k | 0.16% $ 1.2m | |
| Non-Executive Independent Director | 8.3yrs | US$164.20k | 0.51% $ 4.0m | |
| Member of Advisory Board | 11.8yrs | Nessun dato | Nessun dato | |
| Member of Advisory Board | 11.8yrs | Nessun dato | Nessun dato | |
| Non-Executive Independent Director | 8.4yrs | US$164.20k | 0.49% $ 3.8m |
8.3yrs
Durata media
69yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PAYS sono considerati esperti (durata media dell'incarico 8.3 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/20 08:02 |
| Prezzo dell'azione a fine giornata | 2026/08/20 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Paysign, Inc. è coperta da 6 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Gary Prestopino | Barrington Research Associates, Inc. |
| Austin Moldow | Canaccord Genuity |
| Peter Heckmann | D.A. Davidson & Co. |